Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients

Title: Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients
Authors: Nicolazzo C.; Barault L.; Caponnetto S.; Macagno M.; De Renzi G.; Gradilone A.; Belardinilli F.; Cortesi E.; Di Nicolantonio F.; Gazzaniga P.
Contributors: Nicolazzo C.; Barault L.; Caponnetto S.; Macagno M.; De Renzi G.; Gradilone A.; Belardinilli F.; Cortesi E.; Di Nicolantonio F.; Gazzaniga P.
Publication Year: 2020
Collection: Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto)
Subject Terms: Circulating methylated DNA; Circulating tumor DNA; EGFR inhibitor; Liquid biopsy; Metastatic colorectal cancer; RAS mutation clearance
Description: The clearance of RAS mutations in plasma circulating tumor DNA (ctDNA) from originally RAS-mutant metastatic colorectal cancer (mCRC) has been recently demonstrated. Clinical trials investigating whether RAS mutant mCRC who “convert” to wild-type in plasma might benefit from EGFR blockade are ongoing. Detection of tumor-specific DNA methylation alterations in ctDNA has been suggested as a specific tool to confirm the tumoral origin of cell-free DNA. We monitored RAS clearance in plasma from patients with RAS-mutant mCRC at baseline (pre-treatment) (T0); after 4 months of first-line therapy (T1); at the time of first (T2) and second (T3) progression. A five-gene methylation panel was used to confirm the presence of ctDNA in samples in which RAS mutation clearance was detected. At T1, ctDNA analysis revealed wild-type RAS status in 83% of samples, all not methylated, suggesting at this time point the lack of ctDNA shedding. At T2, ctDNA analysis revealed wild-type RAS status in 83% of samples, of which 62.5% were found methylated. At T3, 50% of wild-type RAS samples were found methylated. Non-methylated samples were found in patients with lung or brain metastases. This five-gene methylation test might be useful to confirm the presence of ctDNA in RAS wild-type plasma samples.
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/33291569; info:eu-repo/semantics/altIdentifier/wos/WOS:000601802100001; volume:12; issue:12; firstpage:1; lastpage:8; numberofpages:8; journal:CANCERS; http://hdl.handle.net/2318/1766201; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85097232780; https://www.mdpi.com/2072-6694/12/12/3633/htm
DOI: 10.3390/cancers12123633
Availability: http://hdl.handle.net/2318/1766201; https://doi.org/10.3390/cancers12123633; https://www.mdpi.com/2072-6694/12/12/3633/htm
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.4B0B02AE
Database: BASE